Pharmaceutical forms containing a crystalline active ingredient have the essential disadvantage that, due to the possible presence of the crystalline active ingredient in several polymorphous modifications, the release rate of the active ingredient depends on the polymorphous modification and the crystal size, and thus on the specific surface area of the active ingredient. The dissolution rate of a crystalline substance is not constant, and it changes depending on various shapes and size distribution of the crystals of the active ingredient.